ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
36.26
0.33%
US Tech 100
19,810.80
-0.18%
S&P 500
5,631.22
0.28%
US Dollar vs CAD
1.36884
0.07%
Bitcoin
62,640.14
-3.41%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Summit Therapeutics Inc (SMMT)

  7. Summit Therapeutics Inc (SMMT) News

SMMT

Summit Therapeutics (SMMT)

Summit Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SMMT
DateTimeSourceHeadlineSymbolCompany
02/14/20249:29AMBusiness WireSummit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024NASDAQ:SMMTSummit Therapeutics Inc
02/14/20246:00AMBusiness WireSummit Therapeutics to Host Fourth Quarter & Full Year 2023NASDAQ:SMMTSummit Therapeutics Inc
02/07/20246:00AMBusiness WireSummit Therapeutics to Present at Oppenheimer’s 34th Annual Healthcare Life Sciences ConferenceNASDAQ:SMMTSummit Therapeutics Inc
01/08/20248:07AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
01/08/20248:00AMBusiness WireSummit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SMMTSummit Therapeutics Inc
01/04/20243:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SMMTSummit Therapeutics Inc
01/04/20243:22PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SMMTSummit Therapeutics Inc
01/04/20243:19PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SMMTSummit Therapeutics Inc
01/03/20243:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
01/03/20246:30AMBusiness WireSummit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SMMTSummit Therapeutics Inc
12/13/20233:49PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SMMTSummit Therapeutics Inc
11/07/20237:08AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SMMTSummit Therapeutics Inc
11/07/20237:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
11/07/20236:00AMBusiness WireSummit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023NASDAQ:SMMTSummit Therapeutics Inc
11/02/20233:41PMBusiness WireLaura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical DevelopmentNASDAQ:SMMTSummit Therapeutics Inc
10/31/20233:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
10/31/20237:00AMBusiness WireIvonescimab’s Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023NASDAQ:SMMTSummit Therapeutics Inc
10/26/20237:00AMBusiness WireSummit Therapeutics to Host Q3 2023 Financial Results & Operational Progress Call on November 7, 2023NASDAQ:SMMTSummit Therapeutics Inc
10/19/20237:00AMBusiness WireH. Jack West, MD, Renowned Oncologist & Lung Cancer Expert, Joins Summit Therapeutics as Vice President of Clinical DevelopmentNASDAQ:SMMTSummit Therapeutics Inc
10/16/20236:46AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
10/16/20236:00AMBusiness WireSummit Therapeutics Appoints Proven Biotech Leader Manmeet S. Soni as Chief Operating OfficerNASDAQ:SMMTSummit Therapeutics Inc
09/19/20232:40PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SMMTSummit Therapeutics Inc
09/08/20233:08PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SMMTSummit Therapeutics Inc
08/09/20233:03PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SMMTSummit Therapeutics Inc
08/09/20237:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
08/09/20236:00AMBusiness WireSummit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023NASDAQ:SMMTSummit Therapeutics Inc
08/02/20233:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
08/02/20237:00AMBusiness WireSummit Therapeutics to Host Q2 2023 Financial Results & Operational Progress Call on August 9, 2023NASDAQ:SMMTSummit Therapeutics Inc
06/05/20237:44AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SMMTSummit Therapeutics Inc
06/04/20237:00AMBusiness WirePromising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023NASDAQ:SMMTSummit Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SMMT

Your Recent History

USOTC
AXXA
Exxe (PK)
USOTC
MGON
Megola (PK)
NASDAQ
FFIE
Faraday Future Intellige...
USOTC
IQST
iQSTEL (QX)
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
USOTC
RONN
Ronn Motor (PK)
USOTC
GRST
Ethema Health (PK)
USOTC
WDLF
Decentral Life (PK)
USOTC
FNMA
Fannie Mae (QB)
USOTC
BLEG
Branded Legacy (PK)
USOTC
UBQU
Ubiquitech Software (PK)
USOTC
TPTW
TPT Global Tech (PK)
USOTC
ENZC
Enzolytics (PK)
USOTC
RNVA
Rennova Health (PK)
USOTC
IFUS
Impact Fusion (PK)
USOTC
DBMM
Digital Brand Media and ... (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved